Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 24, Issue 6, 2006, Pages 487-491

  Pagliaro, Lance C ^a   Perez, Cherie A ^a   Tu, Shi Ming ^a   Daliani, Danai D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Capecitabine; Phase II trial; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; CAPECITABINE; CORTICOSTEROID; DOPAMINE; INTERLEUKIN 2; MINERALOCORTICOID; STEROID;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONFUSION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG RESPONSE; DYSPNEA; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERCALCEMIA; HYPOTENSION; KIDNEY CARCINOMA; LUNG EDEMA; MALE; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM HEMORRHAGE; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, RENAL CELL; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33751331925     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2006.03.004     Document Type: Article

References (35)

1. Motzer R.J. Renal cell carcinoma: A priority malignancy for development and study of novel therapies. J Clin Oncol 21 (2003) 1193-1194
2. Rini B.I. New approaches in advanced renal cell carcinoma. Urol Oncol 23 (2005) 65-66
3. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Lancet 353 (1999) 14-17
4. Yang J.C., Sherry R.M., Steinberg S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21 (2003) 3127-3132
5. Motzer R., Murphy B., Mazumdar M., et al. Randomized Phase III trial of interferon alfa-2a versus interferon plus 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 18 (1999) 330a [Abstract 1271]
6. Yagoda A., Abi-Rached B., and Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 22 (1995) 42-60
7. von Roemeling R., Rabatin J.T., Fraley E.E., et al. Progressive metastatic renal cell carcinoma controlled by continuous 5-fluoro-2-deoxyuridine infusion. J Urol 139 (1988) 259-262
8. Dexeus F.H., Logothetis C.J., Sella A., et al. Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. J Urol 146 (1991) 709-713
9. Ellerhorst J.A., Sella A., Amato R.J., et al. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer 80 (1997) 2128-2132
10. Negrier S., Caty A., Lesimple T., et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol 18 (2000) 4009-4015
11. Rini B.I., Vogelzang N.J., Dumas M.C., et al. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 18 (2000) 2419-2426
12. Atzpodien J., Kirchner H., Jonas U., et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22 (2004) 1188-1194
13. Ahlgren J., Lokich J., Auerbach M., et al. Protracted infusional 5FU: A well-tolerated regimen in metastatic renal carcinoma. Proc Am Soc Clin Oncol 12 (1993) 244 [Abstract 763]
14. Masuda F., Nakada J., Kondo I., et al. Adjuvant chemotherapy with vinblastine, Adriamycin, and UFT for renal-cell carcinoma. Cancer Chemother Pharmacol 30 (1992) 477-479
15. Atzpodien J., Kirchner H., Hanninen E.L., et al. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 29A Suppl 5 (1993) S6-S8
16. Ishikawa T., Utoh M., Sawada N., et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55 (1998) 1091-1097
17. Budman D.R., Meropol N.J., Reigner B., et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine. J Clin Oncol 16 (1998) 1795-1802
18. Mackean M., Planting A., Twelves C., et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16 (1998) 2977-2985
19. Gehan E. The determinator of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13 (1961) 346-353
20. Grignon D.J., Ro J.Y., and Ayala A.G. Primary mucin-secreting adenocarcinoma of the kidney. Arch Pathol Lab Med 112 (1988) 847-849
21. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530-2540
22. Wenzel C., Locker G.J., Schmidinger M., et al. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. Am J Kidney Dis 39 (2002) 48-54
23. Padrik P., Leppik K., and Arak A. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: A phase II study. Urol Oncol 22 (2004) 387-392
24. Waters J.S., Moss C., Pyle L., et al. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br J Cancer 91 (2004) 1763-1768
25. Stadler W.M., Halabi S., Ernstoff M.S., et al. A phase II study of gemcitabine and capecitabine in patients with metastatic renal cell cancer: A report of Cancer and Leukemia Group B #90008. J Clin Oncol 22 Suppl 14 (2004) 385s [Abstract 4515]
26. Copur M.S., Ledakis P., Bolton M., et al. An adverse interaction between warfarin and capecitabine: A case report and review of the literature. Clin Colorectal Cancer 1 (2001) 182-184
27. Chang D.Z., Olencki T., Budd G.T., et al. Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics. Cancer Chemother Pharmacol 48 (2001) 493-498
28. Schilsky R.L., Bertucci D., Vogelzang N.J., et al. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol 20 (2002) 582-587
29. Tannir N., Jonasch E., McMichael C., et al. A phase II trial of gemcitabine plus capecitabine in patients with advanced renal cell cancer previously treated with immunotherapy. J Clin Oncol 23 Suppl 16 (2005) 402s [Abstract 4598]
30. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
31. Ratain M., Eisen T., Stadler W., et al. Final findings from a phase II, placebo-controlled, randomized discontinuation trial of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. J Clin Oncol 23 Suppl 16 (2005) 388s [Abstract 4544]
32. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
33. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
34. Siu L.L., Awada A., Takimoto C.H., et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 12 (2006) 144-151
35. Kupsch P., Henning B.F., Passarge K., et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer 5 (2005) 188-196